Browse By Cell Line Result Page of OvirusTdb
The total number of records retrieved from this search are 7. Click on ID to see further detail.
IDOV_4446 | Virus nameHerpes simplex virus | Virus strainG47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for Gamma 34.5, alpha47 and LacZ insertion inactivating ICP6 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineHuman patient | Origin of cell linemalignant leningioma | Cell lineMN7 | Concentration of cell line4000 to 5000 cells per well | In-vitro toxicityNA | AssayMTS assay | In-vitro virus concentration0.001 MOI | In-vitro result68% cell survival after 96 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26951380 |
IDOV_4447 | Virus nameHerpes simplex virus | Virus strainG47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for Gamma 34.5, alpha47 and LacZ insertion inactivating ICP6 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineHuman patient | Origin of cell linemalignant leningioma | Cell lineMN7 | Concentration of cell line4000 to 5000 cells per well | In-vitro toxicityNA | AssayMTS assay | In-vitro virus concentration0.003 MOI | In-vitro result40% cell survival after 96 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26951380 |
IDOV_4448 | Virus nameHerpes simplex virus | Virus strainG47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for Gamma 34.5, alpha47 and LacZ insertion inactivating ICP6 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineHuman patient | Origin of cell linemalignant leningioma | Cell lineMN7 | Concentration of cell line4000 to 5000 cells per well | In-vitro toxicityNA | AssayMTS assay | In-vitro virus concentration0.01 MOI | In-vitro result22% cell survival after 96 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26951380 |
IDOV_4449 | Virus nameHerpes simplex virus | Virus strainG47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for Gamma 34.5, alpha47 and LacZ insertion inactivating ICP6 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineHuman patient | Origin of cell linemalignant leningioma | Cell lineMN7 | Concentration of cell line4000 to 5000 cells per well | In-vitro toxicityNA | AssayMTS assay | In-vitro virus concentration0.03 MOI | In-vitro result18% cell survival after 96 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26951380 |
IDOV_4450 | Virus nameHerpes simplex virus | Virus strainG47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for Gamma 34.5, alpha47 and LacZ insertion inactivating ICP6 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineHuman patient | Origin of cell linemalignant leningioma | Cell lineMN7 | Concentration of cell line4000 to 5000 cells per well | In-vitro toxicityNA | AssayMTS assay | In-vitro virus concentration0.1 MOI | In-vitro result16% cell survival after 96 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26951380 |
IDOV_4451 | Virus nameHerpes simplex virus | Virus strainG47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for Gamma 34.5, alpha47 and LacZ insertion inactivating ICP6 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineHuman patient | Origin of cell linemalignant leningioma | Cell lineMN7 | Concentration of cell line4000 to 5000 cells per well | In-vitro toxicityNA | AssayMTS assay | In-vitro virus concentration0.3 MOI | In-vitro result16% cell survival after 96 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26951380 |
IDOV_4452 | Virus nameHerpes simplex virus | Virus strainG47-delta | Virus genome typeDNA | Virus familyHerpesviridae | Virus genome modificationDeletion mutant for Gamma 34.5, alpha47 and LacZ insertion inactivating ICP6 | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineHuman patient | Origin of cell linemalignant leningioma | Cell lineMN7 | Concentration of cell line4000 to 5000 cells per well | In-vitro toxicityNA | AssayMTS assay | In-vitro virus concentration1 MOI | In-vitro result16% cell survival after 96 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedNA | Immunogenic effectNA | Clinical trialNA | PMID26951380 |